开普拓联合5-FU治疗5-FU耐药的晚期大肠癌  

Effects of camptothecin plus 5-FU in treating patients with 5-FU resistant advanced colorectal cancer

作　　者：邓伟雄[1] 葛轶群[1] 林展雄[1] 温东东[1] 

机构地区：[1]广东省广州市第一人民医院胃肠外科,广东广州510180

出　　处：《中国普通外科杂志》2004年第9期644-646,共3页China Journal of General Surgery

摘　　要：目的　观察开普拓 (CPT 11)联合 5 -氟尿嘧啶 (5 FU )治疗 5 FU耐药晚期大肠癌的效果。方法　随机将 3 0例经 5 FU治疗失败的晚期大肠癌的患者随机分为开CPT 11和CPT 11+ 5 FU组各15例 ,观察两组的近期疗效及不良反应。结果　CPT 11+ 5 FU组有效率为 5 3 .3 3 % ,CPT 11组为3 3 .4% ,有显著性差异 (P 0 .0 5 ) ,且患者的生活质量提高。结论　CPT 11对 5 FU化疗耐药晚期大肠癌患者有效 ;CPT 11联合 5 FU化疗可进一步提高疗效。CCPT 11+ 5 FU可成为一种治疗晚期大肠癌的联合方案。Objective To investigate the effects of camptothecin(CPT 11) plus 5 FU in treating patients with 5 FU resistant advanced colorectal cancer. Methods Thirty patients with advanced colorectal cancer resistant to 5 FU therapy were randomly divided into CPT 11 group and CPT 11+5 Fu (C+F)group. The short term effects and side effects were analysed and the results of the two groups were compared. Results The beneficial effects in CPT 11+5 FU group were 53.33%, while in CPT 11 group were 33.4%(P<0.05).The quality of life in the C+F group patients was improved. Conclusions Use of CPT 11+5 FU in treating patients with advanced colorectal cancer may be better than CPT 11 alone ,and CPT 11+5 FU may be more effective for patients with 5 FU resistant advanced colorectal cancer.

关 键 词：结直肠肿瘤 药物疗法 氟尿嘧啶 治疗应用 开普拓 治疗应用 

分 类 号：R735.32[医药卫生—肿瘤] R977[医药卫生—临床医学]